• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

    5/1/25 8:00:00 AM ET
    $CGON
    Get the next $CGON alert in real time by email

    - Award recipients Honored at the American Urological Association's 2025 Annual Meeting -

    - Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC -

    SCHAUMBURG, Ill. and IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the recipients of the first annual CG-SUO-CTC NMIBC Research Fellowship designed to support the development of outstanding clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). They include:

    • Saum Ghodoussipour, M.D., Rutgers Cancer Institute of New Jersey: Dynamic intra-tumor heterogeneity in non-muscle invasive bladder cancer

    • Taylor Goodstein, M.D., Emory University: Spatial Transcriptomic Profiling of the Tumor Microenvironment in BCG-Unresponsive NMIBC Patients Treated with Novel Intravesical Gene Therapies

    "We were fortunate to receive a number of strong applications for this fellowship," said Colin Dinney, MD, Chairman, Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center. "The Committee is proud to award the fellowship to Drs. Ghodoussipour and Goodstein because their research plans and environment really stood out as having the potential to advance research and drive innovation in urology."

    "It is exciting to see the next generation of urologists bringing passion and commitment to improving bladder cancer care and patient outcomes," said Sia Daneshmand, MD, Director of Urologic Oncology at USC/Norris Comprehensive Cancer Center and Chair of the Bladder Cancer Committee of the SUO-CTC. "We look forward to Drs. Ghodoussipour and Goodstein's presentations at next year's AUA."

    "CG Oncology is honored to partner with the SUO-CTC on this fellowship, and we extend our heartfelt congratulations to Drs. Ghodoussipour and Goodstein," said Ambaw Bellete, President & Chief Operating Officer, CG Oncology. "There remains a significant unmet need in bladder cancer, and this fellowship is an important way to support transformational NMIBC research."

    About Bladder Cancer

    More than 84,000 people are estimated to be diagnosed with bladder cancer in 2025. NMIBC is the most common form of bladder cancer, representing approximately 75% of newly diagnosed cases. Bladder cancer is the sixth most common form of cancer in the United States, and men account for three quarters of newly diagnosed cases. 

    About The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC)

    SUO-CTC is a clinical research investigator network of over 600 members from more than 300 clinical sites in the U.S. and Canada. This national alliance of leading academic and community based uro-oncologists is committed to furthering urology research. The SUO-CTC is a registered 501c3 not-for-profit corporation and has a cooperative relationship with the Society of Urologic Oncology (SUO). To learn more please visit: https://suoctc.org/

    About CG Oncology

    CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.

    Contacts:

    SUO-CTC

    Pam Murphy

    Executive Director, Clinical Research Services

    (847) 264-5978

    [email protected]

    CG Oncology

    Media

    Sarah Connors

    Vice President, Communications and Patient Advocacy, CG Oncology

    (508) 654-2277

    [email protected]

    Investor Relations

    Chau Cheng

    Vice President, Investor Relations, CG Oncology

    (949) 342-8939

    [email protected]



    Primary Logo

    Get the next $CGON alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CGON

    DatePrice TargetRatingAnalyst
    5/2/2025$41.00Overweight
    Analyst
    4/16/2025$23.00Sector Perform
    Scotiabank
    1/7/2025Buy
    TD Cowen
    10/24/2024$60.00Buy
    UBS
    9/23/2024$66.00Outperform
    RBC Capital Mkts
    8/28/2024$65.00Buy
    ROTH MKM
    6/28/2024$65.00Buy
    BofA Securities
    2/20/2024$75.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CGON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Analyst initiated coverage on CG Oncology with a new price target

      Analyst initiated coverage of CG Oncology with a rating of Overweight and set a new price target of $41.00

      5/2/25 8:14:21 AM ET
      $CGON
    • Scotiabank initiated coverage on CG Oncology with a new price target

      Scotiabank initiated coverage of CG Oncology with a rating of Sector Perform and set a new price target of $23.00

      4/16/25 8:09:10 AM ET
      $CGON
    • TD Cowen initiated coverage on CG Oncology

      TD Cowen initiated coverage of CG Oncology with a rating of Buy

      1/7/25 7:46:13 AM ET
      $CGON

    $CGON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Decheng Capital Global Life Sciences Fund Iv, L.P. bought $7,600,000 worth of shares (400,000 units at $19.00) (SEC Form 4) (Amendment)

      4/A - CG Oncology, Inc. (0001991792) (Issuer)

      4/9/24 7:08:23 PM ET
      $CGON

    $CGON
    SEC Filings

    See more
    • CG Oncology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - CG Oncology, Inc. (0001991792) (Filer)

      6/6/25 4:15:27 PM ET
      $CGON
    • Amendment: SEC Form SCHEDULE 13G/A filed by CG Oncology Inc.

      SCHEDULE 13G/A - CG Oncology, Inc. (0001991792) (Subject)

      5/15/25 4:32:25 PM ET
      $CGON
    • SEC Form 10-Q filed by CG Oncology Inc.

      10-Q - CG Oncology, Inc. (0001991792) (Filer)

      5/13/25 8:30:21 AM ET
      $CGON

    $CGON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Graf Susan E

      4 - CG Oncology, Inc. (0001991792) (Issuer)

      6/6/25 5:01:36 PM ET
      $CGON
    • SEC Form 4 filed by Director Post Leonard E

      4 - CG Oncology, Inc. (0001991792) (Issuer)

      6/6/25 5:00:40 PM ET
      $CGON
    • SEC Form 4 filed by Director Song Hong Fang

      4 - CG Oncology, Inc. (0001991792) (Issuer)

      6/6/25 5:00:34 PM ET
      $CGON

    $CGON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

      NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /PRNewswire/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. (NYSE:CLDI) (Profile) is committed to developing a novel approach to treating cancer through the precise delivery of genetic medic

      7/7/25 10:01:00 AM ET
      $CGON
      $CLDI
      $MRK
      $REGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

      NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /PRNewswire/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. (NYSE:CLDI) (Profile) is committed to developing a novel approach to treating cancer through the precise delivery of genetic medic

      7/7/25 8:30:00 AM ET
      $CGON
      $CLDI
      $MRK
      $REGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

      USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,

      6/18/25 11:19:00 AM ET
      $CATX
      $CGON
      $GALT
      $ONCY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CGON
    Leadership Updates

    Live Leadership Updates

    See more
    • Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

      USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,

      6/18/25 11:19:00 AM ET
      $CATX
      $CGON
      $GALT
      $ONCY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CGON
    Financials

    Live finance-specific insights

    See more
    • CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

      - Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients remained free from progression to MIBC at 24 months– - 91.6% of responders remained cystectomy-free at 24 months – - No Grade 3 or greater treatment-related adverse events or deaths reported – - Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M – - Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025 - IRVINE, Calif., April 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:C

      4/26/25 4:10:03 PM ET
      $CGON
    • CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

      IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 8:00 am ET on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) to be presented on April 26, 2025, at a Plenary Session at the American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. Individuals can access the webcast via the link on

      4/24/25 8:00:00 AM ET
      $CGON
    • CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

      - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Naïve (Cohort A) and BCG-Exposed (Cohort B) NMIBC - - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress - - Completed Oversubscribed $238 Million Follow-on Public Equity Offering that Extends Expected Runway into the First Half of 2028 - IRVINE, Calif., March 28, 2025 (GLOBE NEWS

      3/28/25 7:00:00 AM ET
      $CGON

    $CGON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.

      SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

      11/12/24 2:30:47 PM ET
      $CGON
    • Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.

      SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

      11/4/24 10:22:51 AM ET
      $CGON
    • SEC Form SC 13G filed by CG Oncology Inc.

      SC 13G - CG Oncology, Inc. (0001991792) (Subject)

      7/22/24 4:35:57 PM ET
      $CGON